Literature DB >> 27379499

Correlation between ADAMTS13 activity and neurological impairment in acute thrombotic microangiopathy patients.

Giulia Berti de Marinis1, Stefano Novello2, Silvia Ferrari2, Isabella Barzon2, Irene Cortella2, Maria Antonietta Businaro2, Fabrizio Fabris2, Anna Maria Lombardi2.   

Abstract

Differential diagnosis between thrombotic thrombocytopenic purpura (TTP) and other thrombotic microangiopathies (TMA) is usually difficult because of frequently overlapping clinical presentations. Severely depressed ADAMTS13 activity (<10 %) seems distinctive for TTP because of its pathogenetic role. However a long debate exists in the literature about its sensibility and specificity. Our aim was to search for clinical differences between TMA patients referred to our laboratory, comparing them for protease activity <10 versus ≥10 %. ADAMTS13 activity ≥10 % patients (n = 73) showed a higher prevalence of drug- (p = 0.005) and cancer-associated (p < 0.001) TMA. Mean platelet count and renal dysfunction prevalence was lower (p < 0.001), while neurological impairment was more frequent (p = 0.001) in the <10 % ADAMTS13 activity group (n = 109), confirming previous literature findings. When taken neurological manifestations singularly, epilepsy (p = 0.04), focal motor deficit (p < 0.001) and cranial nerve palsy (p = 0.007) were more frequent in the <10 % activity group. In our case series, a <10 % ADAMTS13 activity depicts a group of patients with clinical features similar to TTP patients. Focal motor impairment or epileptic manifestations could further address toward a TTP diagnosis. Studies about treatment efficacy and follow-up are advised to determine whether laboratory findings can guide therapeutic decisions.

Entities:  

Keywords:  ADAMTS13 activity; Epilepsy; TTP; Thrombotic microangiopathy

Mesh:

Substances:

Year:  2016        PMID: 27379499     DOI: 10.1007/s11239-016-1395-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  23 in total

1.  Inverse correlation of free and immune complex-sequestered anti-ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura.

Authors:  S Ferrari; P Knöbl; V Kolovratova; B Plaimauer; P L Turecek; K Varadi; H Rottensteiner; Friedrich Scheiflinger
Journal:  J Thromb Haemost       Date:  2012-01       Impact factor: 5.824

2.  Survival and relapse in patients with thrombotic thrombocytopenic purpura.

Authors:  Johanna A Kremer Hovinga; Sara K Vesely; Deirdra R Terrell; Bernhard Lämmle; James N George
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113

3.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

4.  Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.

Authors:  P M Mannucci; M T Canciani; I Forza; F Lussana; A Lattuada; E Rossi
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

5.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

6.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

7.  Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13).

Authors:  A Tripodi; F Peyvandi; V Chantarangkul; R Palla; A Afrasiabi; M T Canciani; D W Chung; S Ferrari; Y Fujimura; M Karimi; K Kokame; J A Kremer Hovinga; B Lämmle; S F de Meyer; B Plaimauer; K Vanhoorelbeke; K Varadi; P M Mannucci
Journal:  J Thromb Haemost       Date:  2008-07-26       Impact factor: 5.824

8.  Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience.

Authors:  Paul Coppo; Michael Schwarzinger; Marc Buffet; Alain Wynckel; Karine Clabault; Claire Presne; Pascale Poullin; Sandrine Malot; Philippe Vanhille; Elie Azoulay; Lionel Galicier; Virginie Lemiale; Jean-Paul Mira; Christophe Ridel; Eric Rondeau; Jacques Pourrat; Stéphane Girault; Dominique Bordessoule; Samir Saheb; Michel Ramakers; Mohamed Hamidou; Jean-Paul Vernant; Bertrand Guidet; Martine Wolf; Agnès Veyradier
Journal:  PLoS One       Date:  2010-04-23       Impact factor: 3.240

9.  Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura.

Authors:  Friedrich Scheiflinger; Paul Knöbl; Bettina Trattner; Barbara Plaimauer; Gabriele Mohr; Michael Dockal; Friedrich Dorner; Manfred Rieger
Journal:  Blood       Date:  2003-07-10       Impact factor: 22.113

10.  ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment.

Authors:  Erica Rurali; Federica Banterla; Roberta Donadelli; Elena Bresin; Miriam Galbusera; Sara Gastoldi; Flora Peyvandi; Mary Underwood; Giuseppe Remuzzi; Marina Noris
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-04       Impact factor: 8.237

View more
  3 in total

1.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

Review 2.  Severe Thrombotic Thrombocytopenic Purpura (TTP) with Organ Failure in Critically Ill Patients.

Authors:  Sofiane Fodil; Lara Zafrani
Journal:  J Clin Med       Date:  2022-02-19       Impact factor: 4.241

3.  mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice.

Authors:  Susan Liu-Chen; Brendan Connolly; Lei Cheng; Romesh R Subramanian; Zhaozhong Han
Journal:  Sci Rep       Date:  2018-05-18       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.